Partner Content | 01 October 2023 | News
Advancing embolization with purified gelatin
What makes purified gelatin the biomaterial of choice for embolization? Embolization, a medical procedu...Read more
Lab Products | 21 August 2023 | News
Illuminating the Cellular and Molecular Response to Drug Treatment
The Revident Quadrupole Time of Flight (Q-TOF LC/MS) system is ideal for small molecule applications in v...Read more
Healthcare | 01 September 2023 | Opinion
Regulatory Landscape of In Vitro Fertilisation (IVF) Across Asia
Of all the regions on the global stage, Asia-Pacific (APAC) emerges as an intriguing landscape, beaming with o...Read more
Singapore | 01 September 2023 | Opinion
Can you provide an overview of TauRx Therapeutics? TauRx is dedicated to research in neurodegenerative diseas...Read more
Japan | 18 September 2023 | News
Japanese pharma firm Astellas to invest more than €330 M in Ireland facility
Japan headquartered Astellas Pharma has announced its intention to submit a planning application to build a ne...Read more
World | 13 September 2023 | News
AI to transform all processes in drug development by 2026: CPHI report
The first part of the influential CPHI Annual Report predicts sizeable progress ahead for artificial intellige...Read more
Taiwan | 06 September 2023 | News
Bristol Myers Squibb inks $50 M deal to treat immune-mediated diseases in Asia
US-based startup Zenas BioPharma has entered into a license and collaboration agreement with Bristol Myers Squ...Read more
Thailand | 29 September 2023 | News
Thailand Hub of Talents in Cancer Immunotherapy to support advanced research
Thailand Hub of Talents in Cancer Immunotherapy (TTCI), funded by the National Research Council of Thaila...Read more
Korea | 04 September 2023 | News
Korea's IVI renews partnership with CEPI to accelerate development of vaccines
Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vac...Read more
Australia | 30 August 2023 | News
Promising industry-academia partnership in Australia for cancer drug development
Australian pharmaceutical company Phebra and the University of Wollongong (UOW) have announced a new six-year ...Read more
China | 29 September 2023 | News
Chinese University of Hong Kong to further enhance AI in medical education
The Chinese University of Hong Kong (CUHK) recently received a donation of HK$30 million from Li Ka-shing to s...Read more
Korea | 20 September 2023 | News
Partnership in Korea to advance 3D printing medical device technology
Ulsan National Institute of Science and Technology (UNIST), in collaboration with Pusan National University Ya...Read more
World | 18 September 2023 | News
NURA Health Screening Centre by Fujifilm opens in Mongolia
Fujifilm Corporation has announced the upcoming opening of a new "NURA" health screening centre focusing on ca...Read more
Korea | 19 September 2023 | News
ST Pharm invests $110 M in new oligonucleotide facility in Korea
South Korea-based ST Pharm has successfully marked the completion of its groundbreaking ceremony, signaling a ...Read more
China | 18 September 2023 | News
Cytiva expands scientific, digital, and training offering in China
Recognising the long-term needs of the biopharma industry in China and Asia-Pacific, global life sciences lead...Read more
China | 18 August 2023 | News
Global CRO Tigermed opens international headquarters in Hong Kong
Tigermed, a leading global Contract Research Organisation (CRO) providing integrated research and development ...Read more
Multipronged Approach Against Alzheimer’s Disease
In July 2023, Eisai and Biogen received full traditional approval from the United States Food and Drug Administration (US FDA) for their Alzheimer’s drug Leqembi (lecanemab-irmb). This drug is the first to target the disease’s progression rather than merely addressing its symptoms. The approval has infused excitement and hope into the field of Alzheimer’s drug development, known for frequent drug failures. Alzheimer’s Disease (AD) is an escalating global health crisis. In 2020, the World Health Organisation (WHO) noted over 50 million people had dementia worldwide; 60 per cent of them lived in low- to middle-income countries. The Asia Pacific region bears a hefty burden with dementia care costs at $185 billion, straining healthcare in populous economies, according to ADI (Alzheimer’s Disease International). As we mark World Alzheimer’s Day this year on September 21, let’s take a stock of the advancements in the research and development in the Asia Pacific.
For Feedback Email Us: communications@biospectrumasia.com
1 North Bridge Road,
#08-08 High Street Centre,
Singapore 179094
Email : communications@biospectrumasia.com
+65 90150305
